Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages.
Research highlights the inflammatory impacts of ARDS on the heart, underscoring the role of immune responses in cardiovascular complications from viral infections, including COVID-19, and emphasizes the potential of TNF-α neutralizing therapy to mitigate these effects.
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.